SERA PROGNOSTICS, INC. Cost of Revenue
SERA PROGNOSTICS, INC. (SERA) reported Cost of Revenue of $50.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-12
- SERA PROGNOSTICS, INC. cost of revenue for the quarter ending 2026-06-30 was $50.00K, a 21.95% increase year-over-year.
- SERA PROGNOSTICS, INC. cost of revenue for the quarter ending 2026-03-31 was $42.00K, a 5.00% increase year-over-year.
- SERA PROGNOSTICS, INC. cost of revenue for the quarter ending 2025-12-31 was $42.00K, a 31.25% increase year-over-year.
- SERA PROGNOSTICS, INC. cost of revenue for the quarter ending 2025-09-30 was $41.00K, a 215.38% increase year-over-year.
- SERA PROGNOSTICS, INC. cost of revenue for fiscal 2025 was $164.00K, a 100.00% increase from fiscal 2024.
- SERA PROGNOSTICS, INC. cost of revenue for fiscal 2024 was $82.00K, a 60.95% decline from fiscal 2023.
- SERA PROGNOSTICS, INC. cost of revenue for fiscal 2023 was $210.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00K 10-Q · filed 2026-08-12 | $92.00K 10-Q · filed 2026-08-12 | $134.00K derived: sum of 3 quarters · filed 2026-08-12 | $175.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $42.00K 10-Q · filed 2026-05-06 | $84.00K derived: sum of 2 quarters · filed 2026-05-06 | $125.00K derived: sum of 3 quarters · filed 2026-05-06 | $166.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $83.00K derived: sum of 2 quarters · filed 2026-03-18 | $124.00K derived: sum of 3 quarters · filed 2026-08-12 | $164.00K 10-K · filed 2026-03-18 |
| 2025-09-30 | $41.00K 10-Q · filed 2025-11-13 | $82.00K derived: sum of 2 quarters · filed 2026-08-12 | $122.00K 10-Q · filed 2025-11-13 | $154.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $41.00K 10-Q · filed 2026-08-12 | $81.00K 10-Q · filed 2026-08-12 | $113.00K derived: sum of 3 quarters · filed 2026-08-12 | $126.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $40.00K 10-Q · filed 2026-05-06 | $72.00K derived: sum of 2 quarters · filed 2026-05-06 | $85.00K derived: sum of 3 quarters · filed 2026-05-06 | $105.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $45.00K derived: sum of 2 quarters · filed 2026-03-18 | $65.00K derived: sum of 3 quarters · filed 2026-03-18 | $82.00K 10-K · filed 2026-03-18 |
| 2024-09-30 | $13.00K 10-Q · filed 2025-11-13 | $33.00K derived: sum of 2 quarters · filed 2025-11-13 | $50.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $20.00K 10-Q · filed 2025-08-06 | $37.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $17.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $210.00K 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |